Deficient Lmna in fibroblasts: an emerging role of non-cardiomyocytes in DCM

LMNA gene encodes intermediate filament proteins Lamin A/C. Lamin A and Lamin C polymerize to form nuclear lamina, mainly located in the inner layer of the nuclear envelope. As an essential component of the nuclear envelope, Lamins are necessary for nuclear structural integrity and participate in chromatin organization, cell cycle regulation, and DNA damage response [1] . By far, LMNA has the largest and most

to 5%−10% of DCM cases, with an age-related penetrance typically between 30 and 40 [5] . 86% of LMNA mutation carriers exhibit cardiac phenotypes over 40, while 7% of the patients are younger than 20 [4] . LMNA-related DCM usually presents conduction defect and ventricular arrhythmia, with or without progression into left ventricular enlargement [6] . However, how LMNA mutations are linked to the DCM phenotype remains unclear.
Transcriptomic analyses have provided clues to illustrate the pathogenic mechanisms. Abnormal activation of MAPK signaling (ERK1/2, JNK, and p38α) and AKT/mTOR signaling has been found in Lmna H222P/H222P mice, related to the intolerance to energy deficits and decompensation [10] . Upregulation of TGF-β signaling in the Lmna H222P/H222P mouse heart accounts for the myocardial fibrosis. Genes involved in apoptosis, proinflammatory cytokines, DNA damage response, and senescence were upregulated upon the Lmna variant-driven activation of TP53 in Myh6-tTA:tetO-Lmna D300N mice [9] . In Lmna N195K/N195K mice, remodeled connexin expression 40/43 on the lateral surface of cardiomyocytes may impair the gap junction communications, while decreased expression of Hf1b/Sp4 in ventricles may affect the cardiac conduction system [8] .
In addition to in vivo models, patient-specific induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been developed as a new and popular model to mimic human diseases and provide the possibility of precision medicine. Patient-derived hiPSC-CMs carrying LMNA mutations, especially frameshift mutation, are superior models replicating different DCM-related arrhythmia phenotypes and give the opportunities to elucidate the Lamin regulated-calcium handlings mechanism. A patient-derived hiPSC-CMs carrying LMNA S143P , a prevalent mutation in Finland, have shown increased arrhythmia on β-adrenergic stimulation and are more sensitive to hypoxia [11] . Another patient-derived hiPSC-CMs with a frameshift mutation, K117fs, exhibit induced arrhythmias, dysregulation of CAMK2/RYR2 mediated-calcium homeostasis, and electrical abnormalities, consistent with the phenotypes in DCM patients [12] . The aberrant activation of platelet-derived growth factor (PDGF) receptor-β (PDGFRB) due to haploinsufficiency of Lamin A/C is considered to contribute to the arrhythmic phenotype in mutant hiPSC-CMs [12] .
To date, almost all mechanistic studies on LMNA-related DCM have focused on cardiomyocytes, as cardiomyopathy is considered the disease of cardiomyocytes. However, as mentioned at the beginning, LMNA is widely expressed. The gene carrying the casual mutations in CMs is also expressed in other cell lineages, such as fibroblasts. Emerging evidence indicated that cardiac fibroblasts and fibrosis play a significant role in DCM pathogenesis. However, a knowledge gap remains on whether cardiac fibroblasts also participate in the occurrence of LMNA-associated DCM.
Here, Dr. Marian and his team generated a fibroblast-specific Lmna knockout mouse line and demonstrated that the deletion of Lmna in cardiac fibroblasts contributes to senescence-related DCM phenotype [13] . Lmna in fibroblasts was deleted by crossing PDGF receptor-α recombinase (Pdgfra-Cre) and floxed Lmna (Lmna F/F ) mice. Nearly 80% of Lmna was absent in cardiac fibroblasts, confirming the knockout efficiency. The Pdgfra-Cre:Lmna F/F mice showed growth retardation, cardiac conduction defects, arrhythmias, cardiac dysfunction, myocardial fibrosis, increased apoptosis, and premature death within six weeks, recapitulating typical Lmna-DCM phenotypes. Significantly smaller body weights and higher mortality observed in Pdgfra-Cre:Lmna F/F mice are similar to the phenotypes in mice with global or cardiac homozygous Lmna deletion or mutations. Increased LVEDDI and LVMI and decreased LVFS in Pdgfra-Cre:Lmna F/F mice indicated left ventricular dilation and systolic dysfunction. Parallelly, cardiomyocyte hypertrophy was found in Lmna fibroblast-knockout mice. 8/12 of the Pdgfra-Cre:Lmna F/F mice exhibited various arrhythmias. Interestingly, the heterozygous (Pdgfra-Cre:Lmna W/F ) developed a similar but slowly progressing phenotype with disease onset at 12-18 months of age, correlating to an age-associated penetrance in patients and dosage-dependency of laminopathy. Moreover, increased collagen volume fraction combined with elevated TGFβ1 implied progressive myocardial fibrosis in Lmna-deficient mouse hearts. Given that fibroblasts can crosstalk with cardiomyocytes via paracrine signals, extracellular matrix remodeling, and electric coupling, Lmna-deficient fibroblasts may account for those cardiac phenotypes [14] . Escalation of apoptosis was induced by Lmna knockout in conjunction with activation of DNA damage response, likely due to the damaged structure of the nucleus envelope due to Lamin A/C deficiency. Noteworthily, a senescence-associated secretory phenotype (SASP) was discovered in fibroblast-specific Lmna-deleted mice. Incorporating with studies on cardiomyocytes, Lmna deletion in fibroblasts displayed a cohesive phenotype and similar pathogeneses, implying a potential synergetic mechanism between cardiac myocytes and fibroblasts.
In this paper, the authors elaborately defined the progressive DCM phenotype, thoroughly demonstrating the potential role of fibroblasts in LMNA-DCM, and proposed underlining mechanisms. These findings are remarkable as presenting the first direct evidence that fibroblasts participate in the LMNA-regulated DCM pathogenesis. The study provides a new angle on delineating the underlying mechanism for DCM with LMNA mutations. That is, non-cardiomyocytes such as cardiac fibroblasts, and cardiomyocytes, jointly contribute to DCM pathogenesis. This research and future investigations on the function of LMNA in endothelial and smooth muscle cells will further critical new information for clinical treatments.
A few limitations of the study are noted. As the authors mentioned in the discussion, Pdgfra is not a unique marker for cardiac fibroblasts. The Pdgfra promoter-driven Cre expression may lead to partial deletion of LMNA in other cell types and tissues, eventually affecting the net phenotype. To exclude the effect of non-cardiac-fibroblast LMNA deletion, the authors screened the comprehensive metabolic panel, which suggested no apparent abnormalities in liver or kidney, and electrolyte disturbances, except a reduced glucose level in plasma. Interestingly, around 25% of cardiomyocytes showed LMNA deletion in Pdgfra-Cre:Lmna F/F mice. However, Pdgfra-Cre:Lmna W/F mice with intact Lamin A/C expression in cardiomyocytes still developed DCM with a late-onset, implying a fibroblast-independent role in the disease progression. While the lack of highly specific markers for cardiac fibroblasts remains a challenge in the field, the inducible Tcf21-MerCreMer could serve as an alternative approach to confirm the fibroblast contribution to DCM [15] . Additionally, Lmna can be ablated in active myofibroblasts by Postn-MerCreMer to further elucidate the role of fibroblast LMNA in other comorbid cardiovascular diseases such as myocardial infarction and diabetic cardiomyopathy [16,17] .
In summary, the current study filled the knowledge deficiency of cardiac fibroblasts in developing LMNA deficiency-induced cardiomyopathy. The new information expands the understanding of the pathogenesis of the LMNA-induced DCM.